Richard Baird, MD, PhD
Cambridge University Hospitals
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Richard Baird, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:53 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06188520 · A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsAstraZeneca · active not recruiting · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC) · study chair
- Ph1NCT03616587 · Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.AstraZeneca · active not recruiting · ER+ HER2- Advanced Breast Cancer
- Ph1/Ph2NCT02768337 · Cambridge Brain Mets Trial 1Cambridge University Hospitals NHS Foundation Trust · terminated · Lung Cancer, Breast Cancer, Brain Cancer
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.